PCV177 Recruiting Cardiologists and Chronic Heart Patients From A Managed Physician Panel To Support Clinical Studies Phase Iii/Iv Or Health Outcome Studies  by Eichmann, F. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A503
were to home, 25% to rehabilitative care then home, 2% to rehabilitative care then a 
nursing home, 7% to long-term care and 6% of stays ended with a patient death. Of 
a total cost over 1 year of € 610 million (mean cost per patient of € 20,326), 70% con-
cern the post-acute phase. By increasing the proportion of patients thrombolyzed, 
costs are reduced primarily by a decrease in rehabilitative care, with savings per 
additional treated patient of € 1,462. By adding improved timing, savings are more 
than doubled (€ 3,183 per additional patient). ConClusions: By improving throm-
bolytic management in stroke units, patient journeys through care pathways can 
be modified, with increased discharges home, a change in post-acute resource 
consumption and net savings.
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objeCtives: Regulatory hurdles for novel medical devices are lower in Europe 
than in the US. The costs and evidence requirements to achieve CE marking for 
class III devices are lower than to achieve FDA-approval via a PMA submission. As 
such, many companies have chosen to enter European markets with innovative 
cardiac devices before entering the US market. This study sought to understand 
the frequency with which that has occurred in the last 10 years, and the correlation 
between market access timing and cardiac outcomes. Methods: A review of CE 
mark and FDA approvals for class III implantable cardiac devices was conducted for 
the period of 2003-2013. Devices were identified and cross referenced to determine 
which products achieved both CE mark and FDA approval. Those with both, were 
then compared by the date of approval to determine market access variance in the 
US versus Germany. Publically available coverage and reimbursement policies were 
reviewed in each market in combination with relevant disease prevalence rates over 
the study period. Results: Implantable cardiac devices were routinely available in 
Germany before the US during the study period. Early use across Europe, in many 
cases, created additional evidence that was leveraged during the FDA approval and 
follow-on reimbursement assessment processes in the US. While HTAs for devices 
was relatively rare in Germany, similar rates of reimbursement and access were 
achieved in both markets. Rates of cardiovascular associated mortality have dropped 
dramatically, across both markets though rates initiated their decline earlier in 
Germany. ConClusions: Germans benefited from earlier access to many innova-
tive implantable cardiac devices during the period of 2003 to 2013, as compared to 
their American counterparts. The link between early access, clinical outcomes, and 
cost needs to be further analyzed in future studies.
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objeCtives: To identify cardiologists willing to participate in Health outcome or 
Clinical Studies Phase III/IV in internal medicine and to include patients for out-
come assessment. Real life and Peri/Post-Approval Studies are becoming more and 
more important to meet regulatory and market access needs. The objective of the 
present contribution is to assess the benefits of a managed panel of cardiologists 
for site and patient recruitment. Methods: In 2012, a representative survey among 
members of a managed physician panel of cardiologists in US, UK, GER, FR, IT and 
SP was conducted. 208 cardiologists reported on former experiences with clinical 
studies phase III/IV and other post-approval studies, their willingness to participate 
in future studies and their potential adherence to requirements of Good Clinical 
Practice rules. Results: 87,6% of the cardiologists reported to have formerly par-
ticipated in clinical studies phase III/IV, and 54,3% in post-approval studies. Over 
58% of these cardiologists were willing to participate in future studies (58,2% in 
clinical studies phase III/IV and 63,1% in other post-approval studies). More than 
92,7% of this group was ready to be named as principal investigator to an ethical 
committee, to report serious events to the sponsor (97,6%), or to participate in a 
web-based training session (90,3%). Within one month cardiologists see in average 
175 patients suffering from chronic heart disease in their practices (Minimum: 20; 
Maximum more than 500). 93,5% of the cardiologists are willing to ask their patients 
for informed consent for participation in studies, thereby providing a promising 
source for recruiting patients. ConClusions: Cardiologists from a managed panel 
are a time- and cost-effective option for recruiting sites and patients for obser-
vational post-approval outcome and safety studies in the big 5 EU countries and 
the US. Patient incidence estimates are a reliable source for enrollment planning.
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heaLth Care stakehoLders’ eVaLuation of a user-friendLy tooL 
WhiCh estimates Long-term heaLth gains foLLoWing the reduCtion 
of LdL LeVeLs
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objeCtives: Demonstration of long-term value of preventive care in terms of health 
gains and avoided costs associated with disease progression may be of great value 
for those who need to prioritize health policies. This analysis aimed to evaluate 
physicians’ and primary care payers’ opinions about a user-friendly tool which esti-
mates long-term health gains following LDL-C reduction. Methods: A user-friendly 
tool was developed based on a previously published Markov model employed to 
evaluate health outcomes, including cardiovascular (CV) events and due costs. The 
model incorporated Framingham risk equations, Portuguese population characteris-
tics, national mortality rates and local costs. Software runs in iOS and the user may 
simulate for 3, 5 and 10 years the expected CV events drop following a given LDL-C 
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objeCtives: Hospital admissions for congestive heart failure (CHF) are a major 
driver of costs for health systems, and CHF is especially prevalent in patients 
aged 65 and older. This study assessed whether provision of oral nutritional sup-
plements (ONS) in the hospital can reduce these costs, by estimating the effect 
of ONS use on 30-day readmission rates, length of stay (LOS), and hospitaliza-
tion episode costs. Methods: Using the 2000-2010 Premier Research database, 
a large US hospital episode database, we extracted a sample of episodes among 
patients aged 65 and older with a primary diagnosis of CHF. We excluded episodes 
involving tube feeding and those ending in death (due to censoring). Using pro-
pensity score matching, we created a 1: 1 matched sample of ONS and non-ONS 
episodes. We applied ordinary least squares (OLS) and instrumental variables 
(IV) regression analyses to investigate the outcomes of ONS use. The key out-
comes studied were 30-day readmission rates, LOS, and episode costs (measured 
in 2010 US$). Results: Propensity score matching produced a matched sample 
of 38,418 CHF episodes. Naïve OLS analysis, which did not account for selection 
bias, suggested that ONS increased costs, LOS, and probability of 30-day readmis-
sion. However, using IV regression analysis to control for selection bias revealed 
that ONS use reduced the probability of readmission within 30 days by 10.1%, 
from 0.387 to 0.360 (p< 0.01). LOS was reduced through ONS use by 1.28 days 
(14.2%), from 9.03 to 7.75 (p< 0.01). Episode costs were significantly lower with 
ONS use, reducing medical expenditures by $1,266 (7.8%), from $16,166 to $14,900 
(p< 0.01). ConClusions: In elderly patients hospitalized with CHF, ONS improves 
30-day readmission, LOS, and episode cost outcomes. ONS use could provide a 
low-cost strategy for improving hospitalization outcomes for elderly patients with 
CHF and reducing burden on health systems from CHF.
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objeCtives: The choice of stent used in percutaneous coronary intervention (PCI) 
is often at the discretion of the interventional cardiologist (IC) without informed 
shared decision making. We aim to assess the impact of ICs’ awareness of the risk of 
delayed arterial healing associated with drug-eluting stents (DES) on patient knowl-
edge transfer. Methods: 132 ICs from 11 countries (3 Asian: Malaysia, Hong Kong, 
Singapore and 8 European: Germany, Italy, UK, The Netherlands, Belgium, Denmark, 
Russia and Serbia) were invited to complete an online survey using a 4-point scale 
regarding their (i) familiarity with delayed arterial healing associated with DES; (ii) 
how concerned they are about delayed arterial healing; (iii) frequency they discuss 
this risk with their patients and (iv) frequency this risk influence the type of stent they 
use. Responses from Asian cardiologists were compared with Europeans. Results: 
43.2% ICs were Asians and 56.8% were Europeans. Majority of IC were extremely/
very familiar with the risk of delayed arterial healing after DES implantation (63.2% 
Asian vs. 56.0% European, p= NS). IC who were extremely/very concerned about the 
risk of delayed healing were more likely to discuss with their patients (Odds Ratio 
(OR) 2.62, 95% confidence interval (CI) 1.17-5.85, p< 0.01) and influence their stent 
choice (OR 5.56,95%CI 2.56-12.05, p< 0.01). Although twice as many Asian compared 
to European ICs were extremely/very concerned about delayed arterial healing with 
DES (59.6% vs. 32.4%, respectively, p< 0.01), there were no significant differences in the 
frequency this risk was discussed with patients (often/always: 24.6% Asian vs. 26.7% 
European, P= NS) or influence the type of stent used (often/always: 47.4% vs. 35.7%, 
P= NS). ConClusions: Many patients are not well informed of the risk associated 
with DES despite high level of physician awareness and concern of this risk. This 
knowledge transfer gap exists in both Asia and Europe.
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objeCtives: This study aims to evaluate the current management and associ-
ated costs of acute ischemic stroke (AIS) for patients admitted in stroke units 
in France and over a 1 year follow-up period as well as to assess the impact 
of improved thrombolytic management in terms of increasing the proportion 
of patients receiving thrombolysis and/or treated within 3hrs from symptom 
onset on functional recovery and care pathways. Methods: A decision model 
was developed, comprising two components: the first corresponding to the acute 
hospital management phase of patients with AIS up until hospital discharge and 
the second corresponding to the post-acute phase. Patient journeys and costs were 
determined for both phases. Improved thrombolytic management was modeled 
by increasing the proportion of patients receiving thrombolysis from the current 
estimated level of 16.7 to 25% as well as subsequently increasing the proportion of 
patients treated within 3 hours of the onset of symptoms post-stroke from 50 to 
100%. The impact on care pathways was derived from clinical data. Results: In 
2011, 29,999 stays took place in a stroke unit for AIS in France. 60% of discharges 
